Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | STK17B | O94768 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.41 |
| ▸ | AR | P10275 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL130234 | 0.79 | RET (0.77) | RETKDRSTK17BCYP19A1ADORA3 | |
| SCHEMBL3439134 | 0.79 | RET (0.77) | RETKDRSTK17BCYP19A1ADORA3 | |
| SCHEMBL3362960 | 0.79 | RET (0.77) | RETKDRSTK17BCYP19A1ADORA3 | |
| SCHEMBL29367518 | 0.79 | RET (0.77) | RETKDRSTK17BCYP19A1ADORA3 | |
| SCHEMBL29843330 | 0.79 | RET (0.77) | RETKDRSTK17BCYP19A1ADORA3 | |
| SCHEMBL24115843 | 0.79 | RET (0.77) | RETKDRSTK17BCYP19A1ADORA3 | |
| SCHEMBL69727 | 0.79 | RET (0.53) | RETKDRSTK17BCYP19A1ADORA3 | |
| SCHEMBL29963529 | 0.78 | RET (0.49) | RETKDRSTK17BCYP19A1ADORA3 | |
| SCHEMBL501137 | 0.78 | RET (0.49) | RETKDRSTK17BCYP19A1ADORA3 | |
| SCHEMBL6081753 | 0.73 | MEN1 (0.55) | RETKDRADORA3KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023180813-A1 | NARINGENIN OR DERIVATIVES THEREOF FOR IMPROVING SKELETAL MUSCLE ENDURANCE OR FOR TREATING OR PREVENTING MUSCLE ATROPHY OR DYSTROPHY | INSTITUTE OF BIOPHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2023-09-28 | — | — | WO | disclosed |
| US-20100160351-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA AND RELATED DISORDERS | NUON THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| EP-0129636-A1 | Process for the preparation of chromen derivatives | ALKALOIDA VEGYéSZETI GYáR (HU) | 1985-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160351-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA AND RELATED DISORDERS | XDH, SLC10A1, SLC10A6 | RET 280/4885KDR 3558/4885STK17B 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.